Hepatic accumulation of pyrophosphate during acetate metabolism.

Hepatic accumulation of pyrophosphate during acetate metabolism. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hepatic accumulation of pyrophosphate during acetate metabolism. Abstract Text:

T Yamada,T Inoue,T Nishida,E Furuya,K Tagawa,

Accumulation of pyrophosphate induced by acetate administration was investigated in rat liver in situ and in perfused rat liver. Intraperitoneal injection of acetate into rats increased the pyrophosphate concentration in the liver to about 2 mumol/g liver, which was 200 times that in control liver. Perfusion of liver with acetate alone did not result in accumulation of pyrophosphate. However, the further addition of a Ca2+-mobilizing hormone, such as noradrenaline or angiotensin II, together with glucagon to the perfusion medium containing 1 mM acetate caused accumulation of pyrophosphate to a similar level to that observed in vivo. Acetate, glucagon and a Ca2+-mobilizing hormone were all required for accumulation of pyrophosphate in perfused liver. Omission of Ca2+ from the perfusion medium or addition of a Ca2+-antagonist reduced the accumulation significantly. The two kinds of hormones, glucagon and an alpha-agonist, either singly or in combination, did not affect the rate of acetate utilization. These results show that liver cells accumulate a large amount of pyrophosphate during acetate metabolism at high intracellular levels of Ca2+ that can be realized by the synergistic actions of the two kinds of hormones.

Hepatic accumulation of pyrophosphate during acetate metabolism. Publishing Authors By Initials

T Yamada,T Inoue,T Nishida,E Furuya,K Tagawa,

For similar animals: animal population groups: animals, inbred strains: rats, inbred strains research abstracts see: animals: animal population groups: animals, inbred strains: rats, inbred strains research

PUBMED ID PMID:

MEDLINE DATE:

Hepatic accumulation of pyrophosphate during acetate metabolism. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of biochemistry

VOLUME: 104

Page Numbers: 847-50

Journal Abbreviation: J. Biochem.

ISSN: 0021-924X

DAY: 19

MONTH: Nov

YEAR: 1988

Hepatic accumulation of pyrophosphate during acetate metabolism. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376600

Hepatic accumulation of pyrophosphate during acetate metabolism. Keywords Mesh Terms:

KEYWORDS: Rats, Inbred Strains

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Hepatic accumulation of pyrophosphate during acetate metabolism. Information

Substance Name: Glucagon

Registry Number: 9007-92-5

Grant and Affiliation Information for Hepatic accumulation of pyrophosphate during acetate metabolism.

AFFILIATION: Department of Physiological Chemistry, Medical School, Osaka University.

Country: JAPAN

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Biochem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hepatic accumulation of pyrophosphate during acetate metabolism Related Publications

• 8-Epi-iridodial glucoside from Boschniakia rossica.
• A direct colorimetric method for the determination of phospholipids with dithiocyanatoiron reagent.
• A simple method for measuring phosphatidylcholine as its hydrophobic complex with tetrathiocyanatocobaltate.
• A stabilizing factor of yeast mitochondrial F1F0-ATPase-inhibitor complex: common amino acid sequence with yeast ATPase inhibitor and E. coli epsilon and bovine delta subunits.
• Amino acid sequence of an intrinsic inhibitor of mitochondrial ATPase from yeast.
• An immuno-light- and electron-microscopic study of the expression of bone morphogenetic protein-2 during the process of ectopic bone formation in the rat.
• Binding of intrinsic ATPase inhibitor to mitochondrial ATPase--stoichiometry of binding of nucleotides, inhibitor, and enzyme.
• Binding properties of 9K protein to F1-ATPase: a counterpart ligand to the ATPase inhibitor.
• Binding properties of an intrinsic ATPase inhibitor and occurrence in yeast mitochondria of a protein factor which stabilizes and facilitates the binding of the inhibitor to F1F0-ATPase.
• Botulinum toxin treatment for blepharospasm associated with myasthenia gravis.
• Cell-free synthesis of mitochondrial ATPase inhibitor precursor and its transport into yeast mitochondria.
• Change in P-450 content accompanying aerobic formation of mitochondria in yeast.
• Characterization of the development of ectopic chondroid/bone matrix and chondrogenic/osteogenic cells during osteoinduction by rhBMP-2: a histochemical and ultrastructural study.
• Decrease in mitochondrial levels of adenine nucleotides and concomitant mitochondrial dysfunction in ischemic rat liver.
• Development of mitochondrial membranes in anaerobically grown yeast cells.
• Energy-independent protection of the oxidative phosphorylation capacity of mitochondria against anoxic damage by ATP and its non-metabolizable analogs.
• Existence of stoichiometric amounts of an intrinsic ATPase inhibitor and two stabilizing factors with mitochondrial ATP synthase in yeast.
• Hepatic accumulation of pyrophosphate during acetate metabolism.
• Interaction of mitochondrial aspartate aminotransferase with negatively charged lecithin liposomes.
• Involvement of Ca2+ release and activation of phospholipase A2 in mitochondrial dysfunction during anoxia.
• Kinetics of hydroperoxide degradation by NADP-glutathione system in mitochondria.
• Localization of cytochrome c peroxidase in anaerobically grown yeast cells.
• Non-mitochondrial electron transfer system in anaerobically grown yeast cells.
• Partial amino terminal sequence of the precursor of mitochondrial ATPase inhibitor protein synthesized with mRNA partially purified by gel permeation chromatography.
• Properties of binding sites for adenine nucleotides on ATPase from yeast mitochondria.
• Purification and properties of factors in yeast mitochondria stabilizing the F1F0-ATPase-inhibitor complex.
• Simultaneous bindings of ATPase inhibitor and 9K protein to F1F0-ATPase in the presence of 15K protein in yeast mitochondria.
• [Hypertension in dialysis patients]
• [Hypotension in dialysis patients]
• pH-Induced conformational change of ATPase inhibitor from yeast mitochondria. A proton magnetic resonance study.